Managing common side effects GLP-1 medications share common side effects that can be managed effectively with the right approach
In females, L2-Cmu mAb treatment led to a slight, albeit significant reduction in red blood cells (RBCs), hemoglobin (Hb), hematocrit (Hct), white blood cells (WBCs), lymphocytes (Supplementary Table 2), and serum phosphorus (Supplementary Table 3), though most values, with the exception of WBCs, remained within the normal range, and were less severely affected than previously reported with Ganitumab in young CD1 mice 26
Sep 1982;20(9):434-437
How to Inject BPC-157 Safely Under Medical Guidance Subcutaneous Injections: Simple and Effective Best for: Systemic healing or mild injuries Location: Abdomen or near the injured area Needle: 2931 gauge, inch Technique Clean vial top and skin with an alcohol pad Draw reconstituted peptide with a sterile syringe Pinch skin and inject at a 4590 angle Dispose of the needle properly Intramuscular Injections: Deeper Targeting Best for: Deep tissue, ligament, or tendon repair Needle: 2730 gauge, 1 inch Inject near injury site for maximum effect Rotate injection sites to prevent irritation Stacking BPC-157 With Other Peptides BPC-157 + TB-500 Goal: Accelerate healing and flexibility Protocol: BPC-157 250500 mcg daily (local injection) TB-500 25 mg weekly (divided doses) These two peptides complement each other: BPC-157 targets the injured tissue, while TB-500 promotes systemic healing
Body weight Trial endpoints used weekly or monthly weights with a standardized scale